KR20240038996A - 코로나바이러스 관련 질환의 치료를 위한 화합물 및 조성물 - Google Patents
코로나바이러스 관련 질환의 치료를 위한 화합물 및 조성물 Download PDFInfo
- Publication number
- KR20240038996A KR20240038996A KR1020247005669A KR20247005669A KR20240038996A KR 20240038996 A KR20240038996 A KR 20240038996A KR 1020247005669 A KR1020247005669 A KR 1020247005669A KR 20247005669 A KR20247005669 A KR 20247005669A KR 20240038996 A KR20240038996 A KR 20240038996A
- Authority
- KR
- South Korea
- Prior art keywords
- isoquinolin
- carbonitrile
- oxoimidazolidine
- substituted
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163224793P | 2021-07-22 | 2021-07-22 | |
| US63/224,793 | 2021-07-22 | ||
| US202163289009P | 2021-12-13 | 2021-12-13 | |
| US63/289,009 | 2021-12-13 | ||
| PCT/IB2022/056712 WO2023002409A1 (en) | 2021-07-22 | 2022-07-20 | Compounds and compositions for the treatment of coronaviral related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240038996A true KR20240038996A (ko) | 2024-03-26 |
Family
ID=82742919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247005669A Pending KR20240038996A (ko) | 2021-07-22 | 2022-07-20 | 코로나바이러스 관련 질환의 치료를 위한 화합물 및 조성물 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250092016A1 (https=) |
| EP (1) | EP4373814A1 (https=) |
| JP (1) | JP2024527424A (https=) |
| KR (1) | KR20240038996A (https=) |
| AU (1) | AU2022315058A1 (https=) |
| CA (1) | CA3226758A1 (https=) |
| MX (1) | MX2024000986A (https=) |
| PY (1) | PY2261702A (https=) |
| TW (1) | TW202321210A (https=) |
| UY (1) | UY39863A (https=) |
| WO (1) | WO2023002409A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL300412A (en) | 2020-08-24 | 2023-04-01 | Gilead Sciences Inc | Phospholipid compounds and their uses |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| AU2022306289A1 (en) | 2021-07-09 | 2024-01-18 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| JP7624093B2 (ja) | 2022-04-08 | 2025-01-29 | 塩野義製薬株式会社 | ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物 |
| WO2024031089A1 (en) | 2022-08-05 | 2024-02-08 | Gilead Sciences, Inc. | Sars-cov2 main protease inhibitors |
| WO2025125695A2 (en) * | 2024-12-17 | 2025-06-19 | Medchemica Consultancy Ltd | Chemical compoundsid50000167790940 p. doc 2025-05-07 filing no.:19 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1200825B (de) * | 1962-01-13 | 1965-09-16 | Hoechst Ag | Verfahren zur Herstellung von 3, 5-Dioxo-triazolidinen |
| WO2010149755A1 (en) * | 2009-06-26 | 2010-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
-
2022
- 2022-07-19 UY UY0001039863A patent/UY39863A/es unknown
- 2022-07-19 TW TW111127023A patent/TW202321210A/zh unknown
- 2022-07-19 PY PY202202261702A patent/PY2261702A/es unknown
- 2022-07-20 CA CA3226758A patent/CA3226758A1/en active Pending
- 2022-07-20 EP EP22748094.4A patent/EP4373814A1/en active Pending
- 2022-07-20 MX MX2024000986A patent/MX2024000986A/es unknown
- 2022-07-20 WO PCT/IB2022/056712 patent/WO2023002409A1/en not_active Ceased
- 2022-07-20 KR KR1020247005669A patent/KR20240038996A/ko active Pending
- 2022-07-20 JP JP2024503613A patent/JP2024527424A/ja active Pending
- 2022-07-20 AU AU2022315058A patent/AU2022315058A1/en active Pending
- 2022-07-20 US US18/580,986 patent/US20250092016A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024000986A (es) | 2024-02-12 |
| PY2261702A (es) | 2023-06-14 |
| TW202321210A (zh) | 2023-06-01 |
| US20250092016A1 (en) | 2025-03-20 |
| UY39863A (es) | 2023-02-28 |
| EP4373814A1 (en) | 2024-05-29 |
| AU2022315058A1 (en) | 2024-02-08 |
| CA3226758A1 (en) | 2023-01-26 |
| WO2023002409A1 (en) | 2023-01-26 |
| JP2024527424A (ja) | 2024-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7623943B2 (ja) | Ｉｒａｋ分解剤およびそれらの使用 | |
| KR20240038996A (ko) | 코로나바이러스 관련 질환의 치료를 위한 화합물 및 조성물 | |
| AU2018221812B2 (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| JP7097373B2 (ja) | キナーゼ阻害剤としてのアミノトリアゾロピリジン | |
| EP3102572B1 (en) | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| JP6735330B2 (ja) | Ｔｒｐａ１調節因子として有用な置換複素環式スルホンアミド化合物 | |
| JP2025098031A (ja) | Ｔｙｋ２阻害剤およびその使用方法 | |
| US11053234B2 (en) | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | |
| RU2632870C2 (ru) | Трициклические гетероциклические соединения и ингибиторы jak | |
| TWI770501B (zh) | 抗b型肝炎病毒(hbv)之新穎吲哚-2-羧醯胺活性劑 | |
| CN104024254A (zh) | 作为c-Kit激酶抑制剂的化合物和组合物 | |
| TW201930315A (zh) | 具抗b型肝炎病毒(hbv)活性之新穎高活性胺基-噻唑取代之吲哚-2-甲醯胺 | |
| CA2778174A1 (en) | Tricyclic pyrazol amine derivatives as pi3k inhibitors | |
| EP3523292B1 (en) | Heteroaryl compounds and their use as mer inhibitors | |
| TW201625625A (zh) | 做為ｐｄｅ２抑制劑之經取代的［１，２，４］三唑并［１，５－ａ］嘧啶－７－基化合物 | |
| WO2022224223A1 (en) | Compounds and compositions for the treatment of coronaviral related diseases | |
| WO2022165530A1 (en) | Small molecule inhibitors of salt inducible kinases | |
| CA3234429A1 (en) | Ras inhibitors, compositions and methods of use thereof | |
| TW201805277A (zh) | 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途 | |
| CA3074059A1 (en) | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | |
| EA050666B1 (ru) | Соединения и композиции для лечения заболеваний, связанных с коронавирусной инфекцией | |
| CN117651699A (zh) | 用于治疗冠状病毒相关疾病的化合物和组合物 | |
| JP2026506656A (ja) | Ｓｇｋ１阻害剤としてのアミノ置換ピロロトリアジン誘導体 | |
| US20250026763A1 (en) | Egfr inhibitors and methods of use thereof | |
| TW202604512A (zh) | Tiparp抑制劑化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |